Drug Trial Radar · NCT07265479
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
187
Actual
Start
Dec 29, 2025
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 months, up to 23 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
Tapinarof cream, 1%Drug
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
Vehicle CreamDrug
Applied topically once daily to lesions on participant's skin during the Double-Blind period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
- Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label PeriodTime frame: Baseline to the end of the Open-Label Period, up to 56 weeks.
Locations
46 sites in 2 countries. Site status is shown where the registry gives one.
AllerVie Clinical Research
Birmingham, Alabama
Dermatology Trial Associates
Bryant, Arkansas
Dermatology Research Associates
Los Angeles, California
Integrative Skin Science and Research
Sacramento, California
Allergy and Asthma Medical Group and Research Center
San Diego, California
Clinical Trials Research Institute
Thousand Oaks, California
Clarity Dermatology
Castle Rock, Colorado
Skin Care Research, LLC.
Boca Raton, Florida
APEX Clinical Trials
Jacksonville, Florida
TruDerm Research
Wellington, Florida
Cleaver Medical Group Dermatology, Inc
Cumming, Georgia
Ada West Research
Meridian, Idaho
Endeavor Health Clinical Trials Center
Skokie, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
Equity Medical, LLC
Bowling Green, Kentucky
Lawrence J Green, MD LLC
Rockville, Maryland
Oakland Hills Dermatology
Auburn Hills, Michigan
Minnesota Clinical Study Center
New Brighton, Minnesota
SKY Integrative Medical Center
Ridgeland, Mississippi
MediSearch Clinical Trials
Saint Joseph, Missouri
Skin Cancer and Dermatology Institute
Reno, Nevada
Forest Hills Dermatology Group
Kew Gardens, New York
Bobby Buka MD, PC
New York, New York
Equity Medical, LLC
The Bronx, New York
The University of North Carolina Dermatology and Skin Cancer Center
Chapel Hill, North Carolina
Dermatologists of Central States, LLC
Fairborn, Ohio
Allergy Asthma and Clinical Research Center
Oklahoma City, Oklahoma
Oregon Dermatology and Research Center
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Medical University of South Carolina
Charleston, South Carolina
National Allergy and Asthma Research, LLC.
North Charleston, South Carolina
The University of Texas Health Science Center at Houston
Bellaire, Texas
Dermatology Treatment and Research Center
Dallas, Texas
Stryde Research - Epiphany Dermatology
Southlake, Texas
Dermatology Specialists of Spokane
Spokane, Washington
Dermatology Research Institute
Calgary, Alberta, Canada
CARe Clinic (Central Alberta Research Clinic)
Red Deer, Alberta, Canada
Dr. Chih-Ho Hong Medical Inc.
Surrey, British Columbia, Canada
Manitoba Allergy Research Inc.
Winnipeg, Manitoba, Canada
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.